PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 216
- Registration Number
- NCT00986102
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1452
- Registration Number
- NCT00968812
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00929188
First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 65
- Registration Number
- NCT00927927
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 58
- Registration Number
- NCT00924469
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-02
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 118
- Registration Number
- NCT00911859
A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT00910754
- Locations
- 🇨🇦
BC Cancer Agency-Vancouver, Vancouver, British Columbia, Canada
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1088
- Registration Number
- NCT00887198
A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 69
- Registration Number
- NCT00855361
A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2013-07-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 51
- Registration Number
- NCT00747526
© Copyright 2024. All Rights Reserved by MedPath